No Data
No Data
Editas Medicine Says Its Gene Editing Potential Treatment for Sickle-Cell Disease Found Well-Tolerated in Phase 1/2 Trial
Editas Medicine (EDIT) said Friday that new data in a phase 1/2 trial of its gene-editing cell therapy medicine renizgamglogene autogedtemcel showed its was "well-tolerated" and had a safety profile c
Editas Medicine Reveals Updated Safety And Efficacy Results From The RUBY Trial Of Reni-Cel In 18 Sickle Cell Patients At EHA
All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusionPatients had early normalization of total hemoglobin with a mean within t
Express News | Editas Medicine Inc - All Patients Treated in Edithal Trial Maintained Hemoglobin Levels Above Transfusion Threshold and Are Transfusion-Free
Express News | Editas Medicine Announces New Safety and Efficacy Data From the Edithal Trial of Reni-Cel in 7 Patients With Transfusion-Dependent Beta Thalassemia, Presented at the European Hematology Association (Eha) Annual Congress
Form 144 | Editas Medicine(EDIT.US) Officer Proposes to Sell 127.68K in Common Stocks
SEC FILLINGS DISCLOSED/ May 31, $Editas Medicine(EDIT.US)$ Officer O'Neill Gilmore Neil intends to sell 24,000 shares of its common stock on Jun 3, with a total market value of approximately $127.68K.
The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts
Across the recent three months, 4 analysts have shared their insights on Editas Medicine (NASDAQ:EDIT), expressing a variety of opinions spanning from bullish to bearish.The table below offers a conde
No Data